Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7793957 | 0.63 | KMT2A (0.43) | KMT2AALDH1A1MAPTRXFP1KDM4E | |
| SCHEMBL17242241 | 0.62 | KMT2A (0.39) | KMT2AMAPK1ALDH1A1TSHRRXFP1 | |
| SCHEMBL22016883 | 0.62 | ITGB1 (0.32) | — | |
| SCHEMBL14803801 | 0.60 | LMNA (0.43) | KMT2AMAPK1ALDH1A1RXFP1KDM4E | |
| SCHEMBL474385 | 0.59 | KMT2A (0.49) | KMT2AALDH1A1MAPTTSHRKDM4E | |
| SCHEMBL7802796 | 0.59 | KMT2A (0.40) | KMT2AALDH1A1TSHRKDM4EJAK2 | |
| SCHEMBL479900 | 0.58 | KDM4E (0.51) | KMT2AMAPK1ALDH1A1MAPTNPSR1 | |
| SCHEMBL2739588 | 0.57 | ALDH1A1 (0.47) | KMT2AALDH1A1MAPTRXFP1KDM4E | |
| SCHEMBL2449385 | 0.57 | KDM4E (0.51) | KMT2AMAPK1ALDH1A1MAPTNPSR1 | |
| SCHEMBL10838564 | 0.55 | KDM4E (0.48) | KMT2AALDH1A1MAPTNPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGB4 | KMT2A 3006/4885MAPK1 2119/4885ALDH1A1 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.